These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36412065)

  • 1. Carbon-13 labeling of ibrutinib for human microdosing.
    Gong Y; Salter R
    J Labelled Comp Radiopharm; 2023 Jan; 66(1):4-10. PubMed ID: 36412065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of [
    Kriegelstein M; Hroch M; Marek A
    J Labelled Comp Radiopharm; 2021 Nov; 64(13):500-512. PubMed ID: 34478181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.
    de Vries R; Smit JW; Hellemans P; Jiao J; Murphy J; Skee D; Snoeys J; Sukbuntherng J; Vliegen M; de Zwart L; Mannaert E; de Jong J
    Br J Clin Pharmacol; 2016 Feb; 81(2):235-45. PubMed ID: 26382728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
    de Jong J; Mitselos A; Jurczak W; Cordoba R; Panizo C; Wrobel T; Dlugosz-Danecka M; Jiao J; Sukbuntherng J; Ouellet D; Hellemans P
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00649. PubMed ID: 32945596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential adsorption of an analyte and its D
    Mžik M; Váňová N; Kriegelstein M; Hroch M
    J Pharm Biomed Anal; 2021 Nov; 206():114366. PubMed ID: 34555634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
    DiSogra KY; Tran T; Arnall JR; Janes A; Moore DC; Park SI
    J Oncol Pharm Pract; 2021 Jul; 27(5):1265-1269. PubMed ID: 33106104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
    Ghasoub R; Albattah A; Elazzazy S; Alokka R; Nemir A; Alhijji I; Taha R
    J Oncol Pharm Pract; 2020 Mar; 26(2):487-491. PubMed ID: 31216242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Ball S; Das A; Vutthikraivit W; Edwards PJ; Hardwicke F; Short NJ; Borthakur G; Maiti A
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):87-97.e5. PubMed ID: 31787589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of effector B cells by ibrutinib in systemic sclerosis.
    Einhaus J; Pecher AC; Asteriti E; Schmid H; Secker KA; Duerr-Stoerzer S; Keppeler H; Klein R; Schneidawind C; Henes J; Schneidawind D
    Arthritis Res Ther; 2020 Mar; 22(1):66. PubMed ID: 32228672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Haemorrhagic complications following ibrutinib intake after dermatological surgery].
    Lebas D; Preta LH; Leguern A; Modiano P; Wiart T
    Ann Dermatol Venereol; 2020 Nov; 147(11):775-779. PubMed ID: 32917401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
    Miyaji Y; Ishizuka T; Kawai K; Hamabe Y; Miyaoka T; Oh-hara T; Ikeda T; Kurihara A
    Drug Metab Pharmacokinet; 2009; 24(2):130-8. PubMed ID: 19430168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies.
    Gu H; Wang J; Aubry AF; Jiang H; Zeng J; Easter J; Wang JS; Dockens R; Bifano M; Burrell R; Arnold ME
    Anal Chem; 2012 Jun; 84(11):4844-50. PubMed ID: 22540405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics of Ibrutinib in Healthy Adults.
    Al-Ghazawi M; Saleh MI; Najib O; Salem I; Najib N
    Eur J Drug Metab Pharmacokinet; 2021 May; 46(3):405-413. PubMed ID: 33740218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations.
    Carda JP; Santos L; Mariz JM; Monteiro P; Gonçalves HM; Raposo J; Gomes da Silva M
    Hematology; 2021 Dec; 26(1):785-798. PubMed ID: 34605364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.
    Tobinai K; Ogura M; Ishizawa K; Suzuki T; Munakata W; Uchida T; Aoki T; Morishita T; Ushijima Y; Takahara S
    Int J Hematol; 2016 Jan; 103(1):86-94. PubMed ID: 26588924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
    Gallais F; Ysebaert L; Despas F; De Barros S; Dupré L; Quillet-Mary A; Protin C; Thomas F; Obéric L; Allal B; Chatelut E; White-Koning M
    Clin Pharmacokinet; 2020 Sep; 59(9):1171-1183. PubMed ID: 32328976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib: Pediatric First Approval.
    Keam SJ
    Paediatr Drugs; 2023 Jan; 25(1):127-133. PubMed ID: 36352302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
    Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
    Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.